Search Thermo Fisher Scientific
- Contact Us
- Quick Order
-
Don't have an account ? Create Account
Search Thermo Fisher Scientific
Digital PCR (dPCR) is a leading technology for detection and quantification of rare mutations and target sequences in cancer and disease. With the Applied Biosystems QuantStudio Absolute Q Digital PCR System, researchers can quickly and easily quantify relevant targets by leveraging a simple dPCR workflow backed by the trusted performance of TaqMan probe-based assays.
Precise quantification of rare, single-nucleotide polymorphisms (SNPs) and other mutations over background requires highly sensitive analysis. Because dPCR effectively enriches low-level targets by partitioning samples into individual microchamber reactions, it is uniquely suited for applications requiring quantitative rare target detection, such as liquid biopsy analysis.
Technical note: Rare-target quantification on the the Absolute Q Digital PCR System
Absolute quantification using dPCR eliminates the need for a standard curve, improving both the accuracy and reproducibility of rare-target concentration measurement. dPCR also enables detection of ultra-rare target by leveraging pooling data to overcome limitations of sample input volume and concentration.
Poster: Precision genotyping for EGFR+ NSCLC using multiplexed dPCR on cell-free DNA
Technical Note: Improve sensitivity for rare targets by pooling digital PCR data
With the ability to detect very low fractions of mutant targets in a background of abundant wild-type targets, dPCR is a technology of choice for cancer and genetic disease researchers.
Liquid biopsy testing enables non-invasive biomarker testing to identify and track oncogenic mutations. Liquid biopsies detect cell-free DNA (cfDNA) released from apoptotic and necrotic cells. cfDNA that is released from cancer cells is referred to as circulating tumor DNA, or ctDNA.
Characterizing ctDNA helps researchers detect cancer early, measure therapeutic response, quantify residual tumor burden, and monitor emerging resistance to potential therapies. Because ctDNA fragments are typically short and very low in concentration, the sensitivity of dPCR makes it an ideal tool for ctDNA studies.
Webinar: dPCR in liquid biopsy for management and detection of cancer
Absolute Q Liquid Biopsy dPCR assays enable reproducible, specific detection of known somatic mutations. Each predesigned assay has been validated using controls to detect down to 0.1% variant allele frequency in genes relevant for cancer research.
Absolute Q Liquid Biopsy dPCR assays are:
To order Absolute Q Liquid Biopsy dPCR assays, indicate the desired quantity in the appropriate assay row, then scroll to the bottom of the table and click 'Add to cart'. Follow in-cart instructions to complete your purchase.
Can’t find the assay you’re looking for? Design a digital PCR assay with a self service tool or get help with our design services.
Adapt an existing TaqMan assay for use on the QuantStudio Absolute Q Digital PCR System.
Explore our powerfully simple dPCR platform powered by microfluidic array plate (MAP) technology.
Explore now ›
Find master mixes and microfludic array plates and accessories for use with the QuantStudio Absolute Q dPCR System.
Have questions about implementing dPCR in your lab? Let us help you get started.
*Terms and conditions apply. For complete details of the guarantee, go to thermofisher.com/absoluteqassayguarantee
For Research Use Only. Not for use in diagnostic procedures.